Sequoia Financial Advisors LLC Purchases 11,637 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Sequoia Financial Advisors LLC raised its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 44.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 37,943 shares of the company’s stock after buying an additional 11,637 shares during the period. Sequoia Financial Advisors LLC’s holdings in Takeda Pharmaceutical were worth $502,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of TAK. HighTower Advisors LLC increased its holdings in Takeda Pharmaceutical by 1.5% during the 4th quarter. HighTower Advisors LLC now owns 124,439 shares of the company’s stock valued at $1,648,000 after purchasing an additional 1,852 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Takeda Pharmaceutical by 6.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 58,709 shares of the company’s stock valued at $777,000 after buying an additional 3,392 shares in the last quarter. Generali Investments CEE investicni spolecnost a.s. bought a new position in shares of Takeda Pharmaceutical in the fourth quarter valued at about $132,000. West Family Investments Inc. lifted its position in Takeda Pharmaceutical by 87.7% during the 4th quarter. West Family Investments Inc. now owns 33,468 shares of the company’s stock worth $443,000 after buying an additional 15,638 shares in the last quarter. Finally, Callan Family Office LLC bought a new stake in Takeda Pharmaceutical during the 4th quarter worth about $264,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Up 1.1 %

Shares of NYSE TAK opened at $15.18 on Tuesday. Takeda Pharmaceutical Company Limited has a 1-year low of $12.58 and a 1-year high of $15.24. The company has a 50-day moving average of $13.80 and a two-hundred day moving average of $13.90. The company has a market cap of $48.29 billion, a PE ratio of 37.94, a P/E/G ratio of 0.24 and a beta of 0.46. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, equities analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.